ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Celgene and the computational chemistry company Nimbus Therapeutics are teaming up to advance R&D on small molecules that could treat a suite of immunology conditions. One Nimbus program is designing inhibitors of the inflammation-linked enzyme Tyk2, which has applications in rheumatoid arthritis, Crohn’s disease, multiple sclerosis, and more. A second program for inhibitors of STING (stimulator of interferon genes) could help prevent innate immune system activation in autoimmune diseases like lupus. The pact gives Celgene the option to acquire the Nimbus programs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter